Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axalimogene filolisbac - Advaxis

Drug Profile

Axalimogene filolisbac - Advaxis

Alternative Names: ADXS HPV; ADXS-11-001; ADXS11-001-vaccine; Anal-cancer-vaccine-Advexis; AXAL; Cervical cancer vaccine - Advaxis; Head and neck cancer vaccine - Advaxis; Listeria cancer vaccine - Advaxis; Listeria monocytogenes vaccine live attenuated - Advaxis; Live attenuated listeria monocytogenes vaccine - Advaxis; Lm-Listeriolysin-O-fetal liver kinase-1; Lm-LLO-E7; Lm-LLO-E7 vaccine; Lovaxin-C; NSC-752718; Raligize

Latest Information Update: 03 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advaxis
  • Developer Advaxis; Brown University Medical School; Cancer Research UK; Gynecologic Oncology Group; Icahn School of Medicine at Mount Sinai; MedImmune
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Gene transference; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer; Cervical cancer; Head and neck cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cervical cancer

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Anal cancer; Oropharyngeal cancer
  • Suspended Head and neck cancer
  • Discontinued Cervical intraepithelial neoplasia

Most Recent Events

  • 27 Jul 2018 Regulatory submission withdrawn for Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in European Union (IV)
  • 13 Jul 2018 The US FDA lifts clinical hold from the IND application for a phase I/II trial in HPV-associated Head and neck cancer and Cervical cancer (Combination therapy, Recurrent, Second-line therapy or greater)
  • 07 Jun 2018 Axalimogene filolisbac - Advaxis is available for licensing for HPV-associated cancers, including cervical cancer, as of 07 Jun 2018. https://www.advaxis.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top